Global Chronic Inflammatory Demyelinating Polyneuropathy CIDP Size 2025, Forecast To 2034
26 Mar, 2025
What are the Historical Developments and Current Growth Metrics of the Chronic Inflammatory Demyelinating Polyneuropathy CIDP Market?
The chronic inflammatory demyelinating polyneuropathy cidp market has seen considerable growth due to a variety of factors.
• The market for chronic inflammatory demyelinating polyneuropathy (CIDP) has experienced significant growth in the past few years. The market is projected to expand from a worth of $2.10 billion in 2024 to $2.38 billion in 2025, yielding a compound annual growth rate (CAGR) of 8.4%.
Factors such as a growing elderly population, enhancements in treatment options, heightened awareness leading to early detection, progress in immunology and autoimmune studies, coupled with a rise in autoimmune disease occurrences attribute to this historic period growth.
What Is The Projected Growth Of The Chronic Inflammatory Demyelinating Polyneuropathy CIDP Market Size?
The chronic inflammatory demyelinating polyneuropathy cidp market is expected to maintain its strong growth trajectory in upcoming years.
• In the upcoming years, the market for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) will witness significant expansion, reaching a value of $3.11 billion by 2029 with a Compound Annual Growth Rate (CAGR) of 8.1%.
The predicted growth during this period can be attributed to factors such as an aging global society, increased attention to rare diseases and autoimmune conditions, better healthcare access and patient advocacy, and improved healthcare infrastructure. Major trends that will define this period include the increased occurrence of CIDP, advances in treatment methods, growing R&D activities, the introduction of biosimilar therapies, and the development of tailor-made medical strategies.
What Are The Core Factors Supporting Growth In The Chronic Inflammatory Demyelinating Polyneuropathy CIDP Market?
The growth of the chronic inflammatory demyelinating polyneuropathy (CIDP) market is projected to be spurred by escalating healthcare costs. Healthcare expenditure is on the rise due to enhanced investments in medical facilities, increasing need for sophisticated treatment options, extensive insurance coverage, and government initiatives to improve healthcare accessibility. Spending more on healthcare allows for improved access to state-of-the-art treatments, early detection and efficient management of CIDP, thus improving patient outcomes and quality of lifestyle. For example, the Office for National Statistics, a government department in the UK, reported a 5.6% rise in total healthcare expenditure in nominal terms from 2022 to 2023 in May 2024. This was a considerable upturn compared to the 0.9% growth seen in 2022. Consequently, escalating healthcare costs are fuelling the expansion of the chronic inflammatory demyelinating polyneuropathy (CIDP) market.
What Are The Principal Market Segments In The Global Chronic Inflammatory Demyelinating Polyneuropathy CIDP Industry?
The chronic inflammatory demyelinating polyneuropathy (CIDP) market covered in this report is segmented –
1) By Treatment: Intravenous Immunoglobulin, Corticosteroids, Plasmapheresis, Physiotherapy, Other Treatments
2) By Route Of Administration: Intravenous, Oral, Other Routes Of Administration
3) By Diagnosis: Electrodiagnostic Testing, Nerve Conduction, Electromyography (EMG), Spinal Fluid Analysis, Other Diagnosis
4) By Distribution Channel: Hospitals, Pharmacies, Online Pharmacies, Specialty Clinics
5) By End User: Hospitals, Research Institutions, Homecare Settings
Subsegments:
1) By Intravenous Immunoglobulin (IVIG): Standard IVIG Therapy, High-Dose IVIG Therapy
2) By Corticosteroids: Oral Corticosteroids, Intravenous Corticosteroids
3) By Plasmapheresis: Single-Exchange Plasmapheresis, Multiple-Exchange Plasmapheresis
4) By Physiotherapy: Muscle Strengthening Exercises, Balance And Coordination Therapy
5) By Other Treatments: Immunosuppressive Agents, Monoclonal Antibodies
Which Emerging Market Trends Are Altering The Chronic Inflammatory Demyelinating Polyneuropathy CIDP Industry?
Leading entities in the chronic inflammatory demyelinating polyneuropathy (CIDP) market are prioritizing advancements like intravenous immunoglobulin (IVIG) therapy to augment treatment effectiveness, elevate the quality of patient results, and offer more precise and productive immunomodulation for CIDP control. IVIG therapy, a method that involves infusing highly concentrated antibodies from healthy donors, aids in managing the immune system and curbing inflammation in autoimmune diseases. For example, in January 2024, Japan's Takeda Pharmaceutical Company Limited received FDA authorization for its product, GAMMAGARD LIQUID, to be used as IVIG therapy for adults suffering from CIDP. This recognition permits it to be utilized as a primary therapy, initiated with a starting dose and followed by upkeep doses to ensure sustainable disease control and enhance neuromuscular functionality.
Who Are the Key Players In The Chronic Inflammatory Demyelinating Polyneuropathy CIDP Market?
Major companies operating in the chronic inflammatory demyelinating polyneuropathy (CIDP) market are:
• Pfizer Inc.
• Johnson & Johnson
• Sanofi SA
• Novartis AG
• Takeda Pharmaceutical Company Limited
• Baxter International Inc.
• CSL Behring (CSL Limited)
• Grifols S.A.
• Sun Pharmaceutical Industries Ltd.
• Mitsubishi Tanabe Pharma Corporation
• Octapharma AG
• Cipla Inc.
• Hikma Pharmaceuticals plc
• Halozyme Therapeutics
• Hualan Biological Engineering Inc
• argenx SE
• Hovione
• Nihon Pharmaceutical Co. Ltd.
• Bio Products Laboratory Ltd.
• AdvaCare Pharma.
What Are The Regional Insights Into The Chronic Inflammatory Demyelinating Polyneuropathy CIDP Market?
North America was the largest region in the chronic inflammatory demyelinating polyneuropathy (CIDP) market in 2024. The regions covered in the chronic inflammatory demyelinating polyneuropathy (CIDP) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.